Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: TBL 12 Clear all

Conditions: NSCLC
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 43
States / cities: Phoenix, Arizona • Arcadia, California • Duarte, California + 37 more

Conditions: Obesity
Interventions: Metformin, VI-0521, Sitagliptan, Probenecid; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Safety and Tolerability
Interventions: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days; Drug
Lead sponsor: MerLion Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pain, Acute Postoperative, Breast Disease
Interventions: suzetrigine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Major Depressive Disorder
Interventions: LY2216684, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Anaemia
Interventions: Daprodustat, Darbepoetin alfa, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 36
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 31 more

Conditions: Mood Disorders, Depression, Anxiety, Grief, Bereavement, Health Behavior
Interventions: Behavioral self-monitoring, Behavioral self-monitoring + Motivational interviewing; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions: Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: WSE, Placebo Oral Tablet; Drug
Lead sponsor: Chengappa, K.N. Roy, MD; Other
Eligibility: 18 Years to 64 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Los Angeles, California • Catonsville, Maryland

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: NT0102, Placebo; Drug
Lead sponsor: Neos Therapeutics, Inc; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more

Conditions: Disruptive Behavior, Pediatrics
Interventions: Telehealth Parent Child Interaction Therapy, Telehealth Parent Child Interaction Therapy (Delayed Start); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 2 Years to 7 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Familial Chylomicronemia Syndrome (FCS)
Interventions: LCQ908, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seatlle, Washington

Conditions: Weight Loss, Obesity, Childhood, Obesity
Interventions: Lomaira 8Mg Tablet; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 12 Months to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Loma Linda, California

Conditions: HIV Infections
Interventions: Dasatinib, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Cleveland, Ohio • Seattle, Washington

Conditions: Pregnancy Related, Tobacco Use Disorder
Interventions: Bupropion SR, Smoking Cessation Counseling, Placebo; Drug · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Endometrioma
Interventions: Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hot Flashes, Memory Loss
Interventions: PhytoSERM tablet, placebo; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Coronary Artery Disease
Interventions: Plavix (Clopidogrel); Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pediatric Bipolar Disorder
Interventions: Aripiprazole, fish oil, Placebo; Drug · Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Heart Failure and Reduced Ejection Fraction
Interventions: LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 81
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA, TEZ/IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 32 more

Conditions: Apathy in Dementia
Interventions: CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 17
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 13 more

Conditions: Cardiomyopathy, Renal Impairment
Interventions: Tadalafil, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

Suzetrigine for Non-Mastectomy Breast Surgery

A Study of LY2216684 and Digoxin in Healthy Subjects

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Promoting Widowed Elders Lifestyle After Loss

The CARDIOPROTECT Trial

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Tele-PCIT for Healthy Relationships in Families At-Risk

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Treating Toddler Obesity by Treating the Parent/Caregiver Obesity With Weight Loss Medications

Dasatinib for HIV-1 Reservoir Reduction

Bupropion for Smoking Cessation During Pregnancy

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

Phytoserms for Menopause Symptoms and Age-Associated Memory Decline

Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)